Vitamin B3

Last Updated: September 28 2022

Niacin is an essential B-vitamin. Supplementation results in improved cholesterol and triglyceride levels. However, since a side-effect of supplementation is increased insulin resistance, niacin supplementation only provides benefits for cardiovascular health if precautions are taken.

Vitamin B3 is most often used for

Summary

Vitamin B3 refers to the molecule commonly called nicotinic acid, or niacin, though it may also refer to the other vitamin B3 vitamer, called nicotinamide. Vitamin B3 is necessary to support the function of many enzymes.

Niacin supplementation is very effective at normalizing blood lipid levels. Supplementation increases HDL-C levels and decreases LDL-C and triglyceride levels. This makes niacin look like a great cardioprotective supplement on paper. Unfortunately, niacin supplementation does not reliably result in a reduced risk of cardiovascular disease, possibly because it also increases insulin resistance, which could negate the benefits niacin provides for blood lipid levels.

Niacin supplementation is theorized to benefit cognition and longevity. This is because niacin supplementation increases cellular nicotinamide adenine dinucleotide (NAD+) levels. Preliminary evidence suggests increased NAD+ levels may result in the above benefits, but much more research is needed to determine if this effect actually occurs.

Topical application of nicotinamide is sometimes used for skin health, though it is not as effective as vitamin A. Nicotinamide is used for topical application because it does not result in the flushed skin that niacin supplementation can cause.

Current evidence suggests prolonged niacin supplementation increases insulin resistance because it hinders the ability of insulin to suppress glucose synthesis in the liver. This causes an increase in blood glucose levels, which leads to lowered insulin sensitivity over time, since the relevant receptor is eventually desensitized to the elevated glucose levels in the blood.

The flush caused by niacin supplementation is a temporary effect. Though it may be uncomfortable, it is not harmful. There are many case studies describing people overdosing on niacin in an effort to pass a urine test. Niacin overdose results in multiple organ failure and is not effective at masking a urine test.

What else is Vitamin B3 known as?
Note that Vitamin B3 is also known as:
  • Niacin
  • B3
  • Vitamin B3
Vitamin B3 should not be confused with:
Dosage information

Most of the benefits from niacin supplementation occur after doses of at least one gram. This is approximately 5,000% the recommended daily intake.

Join our supplement information course

Examine Database: Vitamin B3
What works and what doesn't?

Unlock the full potential of Examine

Get started

Don't miss out on the latest research

Frequently asked questions

Other FAQs

References
3.^Sauve AANAD+ and vitamin B3: from metabolism to therapiesJ Pharmacol Exp Ther.(2008 Mar)
4.^Sauve AA1, Youn DYSirtuins: NAD(+)-dependent deacetylase mechanism and regulationCurr Opin Chem Biol.(2012 Dec)
5.^Kurnasov O1, Goral V, Colabroy K, Gerdes S, Anantha S, Osterman A, Begley TPNAD biosynthesis: identification of the tryptophan to quinolinate pathway in bacteriaChem Biol.(2003 Dec)
6.^Fukuwatari T1, Ohta M, Kimtjra N, Sasaki R, Shibata KConversion ratio of tryptophan to niacin in Japanese women fed a purified diet conforming to the Japanese Dietary Reference IntakesJ Nutr Sci Vitaminol (Tokyo).(2004 Dec)
8.^Yang H1, Lavu S, Sinclair DANampt/PBEF/Visfatin: a regulator of mammalian health and longevityExp Gerontol.(2006 Aug)
9.^Pieper JAUnderstanding niacin formulationsAm J Manag Care.(2002 Sep)
11.^Benyó Z1, Gille A, Kero J, Csiky M, Suchánková MC, Nüsing RM, Moers A, Pfeffer K, Offermanns SGPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushingJ Clin Invest.(2005 Dec)
12.^Soudijn W1, van Wijngaarden I, Ijzerman APNicotinic acid receptor subtypes and their ligandsMed Res Rev.(2007 May)
13.^Cantó C1, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y, Fernandez-Marcos PJ, Yamamoto H, Andreux PA, Cettour-Rose P, Gademann K, Rinsch C, Schoonjans K, Sauve AA, Auwerx JThe NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesityCell Metab.(2012 Jun 6)
19.^MacKay D1, Hathcock J, Guarneri ENiacin: chemical forms, bioavailability, and health effectsNutr Rev.(2012 Jun)
23.^Kruse W, Kruse W, Raetzer H, Heuck CC, Oster P, Schellenberg B, Schlierf GNocturnal inhibition of lipolysis in man by nicotinic acid and derivativesEur J Clin Pharmacol.(1979 Aug)
25.^Wise A1, Foord SM, Fraser NJ, Barnes AA, Elshourbagy N, Eilert M, Ignar DM, Murdock PR, Steplewski K, Green A, Brown AJ, Dowell SJ, Szekeres PG, Hassall DG, Marshall FH, Wilson S, Pike NBMolecular identification of high and low affinity receptors for nicotinic acidJ Biol Chem.(2003 Mar 14)
26.^Soga T1, Kamohara M, Takasaki J, Matsumoto S, Saito T, Ohishi T, Hiyama H, Matsuo A, Matsushime H, Furuichi KMolecular identification of nicotinic acid receptorBiochem Biophys Res Commun.(2003 Mar 28)
27.^Lorenzen A1, Stannek C, Burmeister A, Kalvinsh I, Schwabe UG protein-coupled receptor for nicotinic acid in mouse macrophagesBiochem Pharmacol.(2002 Aug 15)
28.^Singh N1, Gurav A2, Sivaprakasam S2, Brady E2, Padia R2, Shi H3, Thangaraju M3, Prasad PD3, Manicassamy S4, Munn DH5, Lee JR6, Offermanns S7, Ganapathy V8Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesisImmunity.(2014 Jan 16)
29.^Taggart AK1, Kero J, Gan X, Cai TQ, Cheng K, Ippolito M, Ren N, Kaplan R, Wu K, Wu TJ, Jin L, Liaw C, Chen R, Richman J, Connolly D, Offermanns S, Wright SD, Waters MG(D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-GJ Biol Chem.(2005 Jul 22)
30.^Jung JK1, Johnson BR, Duong T, Decaire M, Uy J, Gharbaoui T, Boatman PD, Sage CR, Chen R, Richman JG, Connolly DT, Semple GAnalogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109bJ Med Chem.(2007 Apr 5)
31.^Ren N1, Kaplan R, Hernandez M, Cheng K, Jin L, Taggart AK, Zhu AY, Gan X, Wright SD, Cai TQPhenolic acids suppress adipocyte lipolysis via activation of the nicotinic acid receptor GPR109A (HM74a/PUMA-G)J Lipid Res.(2009 May)
32.^Walters RW1, Shukla AK, Kovacs JJ, Violin JD, DeWire SM, Lam CM, Chen JR, Muehlbauer MJ, Whalen EJ, Lefkowitz RJbeta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in miceJ Clin Invest.(2009 May)
33.^Benyó Z1, Gille A, Bennett CL, Clausen BE, Offermanns SNicotinic acid-induced flushing is mediated by activation of epidermal langerhans cellsMol Pharmacol.(2006 Dec)
34.^Maciejewski-Lenoir D1, Richman JG, Hakak Y, Gaidarov I, Behan DP, Connolly DTLangerhans cells release prostaglandin D2 in response to nicotinic acidJ Invest Dermatol.(2006 Dec)
36.^Parson HK1, Harati H, Cooper D, Vinik AIRole of prostaglandin D2 and the autonomic nervous system in niacin-induced flushingJ Diabetes.(2013 Mar)
37.^Kamanna VS1, Ganji SH, Kashyap MLThe mechanism and mitigation of niacin-induced flushingInt J Clin Pract.(2009 Sep)
38.^Sanyal S1, Kuvin JT, Karas RHNiacin and laropiprantDrugs Today (Barc).(2010 Jun)
39.^Lee JY1, Parks JSATP-binding cassette transporter AI and its role in HDL formationCurr Opin Lipidol.(2005 Feb)
41.^Venkateswaran A1, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, Tontonoz PControl of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alphaProc Natl Acad Sci U S A.(2000 Oct 24)
44.^Cavelier C1, Lorenzi I, Rohrer L, von Eckardstein ALipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1Biochim Biophys Acta.(2006 Jul)
45.^Mulya A1, Lee JY, Gebre AK, Boudyguina EY, Chung SK, Smith TL, Colvin PL, Jiang XC, Parks JSInitial interaction of apoA-I with ABCA1 impacts in vivo metabolic fate of nascent HDLJ Lipid Res.(2008 Nov)
46.^Garfagnini A1, Devoto G, Rosselli P, Boggiano P, Venturini MRelationship between HDL-cholesterol and apolipoprotein A1 and the severity of coronary artery diseaseEur Heart J.(1995 Apr)
48.^Denis M1, Haidar B, Marcil M, Bouvier M, Krimbou L, Genest J JrMolecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1)J Biol Chem.(2004 Feb 27)
51.^Usman MH1, Qamar A, Gadi R, Lilly S, Goel H, Hampson J, Mucksavage ML, Nathanson GA, Rader DJ, Dunbar RLExtended-release niacin acutely suppresses postprandial triglyceridemiaAm J Med.(2012 Oct)
52.^Wang W1, Basinger A, Neese RA, Shane B, Myong SA, Christiansen M, Hellerstein MKEffect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride productionAm J Physiol Endocrinol Metab.(2001 Mar)
53.^Sahoo D1, Trischuk TC, Chan T, Drover VA, Ho S, Chimini G, Agellon LB, Agnihotri R, Francis GA, Lehner RABCA1-dependent lipid efflux to apolipoprotein A-I mediates HDL particle formation and decreases VLDL secretion from murine hepatocytesJ Lipid Res.(2004 Jun)
56.^de Murcia G1, Ménissier de Murcia JPoly(ADP-ribose) polymerase: a molecular nick-sensorTrends Biochem Sci.(1994 Apr)
57.^Calabrese CR1, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang LZ, Webber SE, Williams KJ, Curtin NJAnticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361J Natl Cancer Inst.(2004 Jan 7)
62.^Zhang T1, Berrocal JG, Yao J, DuMond ME, Krishnakumar R, Ruhl DD, Ryu KW, Gamble MJ, Kraus WLRegulation of poly(ADP-ribose) polymerase-1-dependent gene expression through promoter-directed recruitment of a nuclear NAD+ synthaseJ Biol Chem.(2012 Apr 6)
63.^Bai P1, Cantó C, Oudart H, Brunyánszki A, Cen Y, Thomas C, Yamamoto H, Huber A, Kiss B, Houtkooper RH, Schoonjans K, Schreiber V, Sauve AA, Menissier-de Murcia J, Auwerx JPARP-1 inhibition increases mitochondrial metabolism through SIRT1 activationCell Metab.(2011 Apr 6)
64.^Surjana D1, Halliday GM, Damian DLRole of nicotinamide in DNA damage, mutagenesis, and DNA repairJ Nucleic Acids.(2010 Jul 25)
65.^Lee HI1, Jang SY, Kang HT, Hwang ESp53-, SIRT1-, and PARP-1-independent downregulation of p21WAF1 expression in nicotinamide-treated cellsBiochem Biophys Res Commun.(2008 Apr 4)
67.^Bechgaard H, Jespersen SGI absorption of niacin in humansJ Pharm Sci.(1977 Jun)
69.^Menon RM1, González MA, Adams MH, Tolbert DS, Leu JH, Cefali EAEffect of the rate of niacin administration on the plasma and urine pharmacokinetics of niacin and its metabolitesJ Clin Pharmacol.(2007 Jun)
73.^Aoyama K1, Matsubara K, Okada K, Fukushima S, Shimizu K, Yamaguchi S, Uezono T, Satomi M, Hayase N, Ohta S, Shiono H, Kobayashi SN-methylation ability for azaheterocyclic amines is higher in Parkinson's disease: nicotinamide loading testJ Neural Transm.(2000)
74.^Brzozowski T1, Konturek PC, Chlopicki S, Sliwowski Z, Pawlik M, Ptak-Belowska A, Kwiecien S, Drozdowicz D, Pajdo R, Slonimska E, Konturek SJ, Pawlik WWTherapeutic potential of 1-methylnicotinamide against acute gastric lesions induced by stress: role of endogenous prostacyclin and sensory nervesJ Pharmacol Exp Ther.(2008 Jul)
75.^Gebicki J1, Sysa-Jedrzejowska A, Adamus J, Woźniacka A, Rybak M, Zielonka J1-Methylnicotinamide: a potent anti-inflammatory agent of vitamin originPol J Pharmacol.(2003 Jan-Feb)
77.^Shehadah A1, Chen J, Zacharek A, Cui Y, Ion M, Roberts C, Kapke A, Chopp MNiaspan treatment induces neuroprotection after strokeNeurobiol Dis.(2010 Oct)
79.^Chen J1, Cui X, Zacharek A, Jiang H, Roberts C, Zhang C, Lu M, Kapke A, Feldkamp CS, Chopp MNiaspan increases angiogenesis and improves functional recovery after strokeAnn Neurol.(2007 Jul)
80.^Mast H1, Thompson JL, Lee SH, Mohr JP, Sacco RLHypertension and diabetes mellitus as determinants of multiple lacunar infarctsStroke.(1995 Jan)
81.^Capes SE1, Hunt D, Malmberg K, Pathak P, Gerstein HCStress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overviewStroke.(2001 Oct)
82.^Ye X1, Chopp M, Cui X, Zacharek A, Cui Y, Yan T, Shehadah A, Roberts C, Liu X, Lu M, Chen JNiaspan enhances vascular remodeling after stroke in type 1 diabetic ratsExp Neurol.(2011 Dec)
83.^Yan T1, Chopp M, Ye X, Liu Z, Zacharek A, Cui Y, Roberts C, Buller B, Chen JNiaspan increases axonal remodeling after stroke in type 1 diabetes ratsNeurobiol Dis.(2012 Apr)
84.^[No authors listedClofibrate and niacin in coronary heart diseaseJAMA.(1975 Jan 27)
87.^Teo KK1, Goldstein LB, Chaitman BR, Grant S, Weintraub WS, Anderson DC, Sila CA, Cruz-Flores S, Padley RJ, Kostuk WJ, Boden WE; AIM-HIGH InvestigatorsExtended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trialStroke.(2013 Oct)
90.^Si Y1, Zhang Y2, Zhao J3, Guo S2, Zhai L2, Yao S1, Sang H1, Yang N2, Song G2, Gu J4, Qin S2Niacin inhibits vascular inflammation via downregulating nuclear transcription factor-κB signaling pathwayMediators Inflamm.(2014)
91.^Lipszyc PS1, Cremaschi GA, Zorrilla-Zubilete M, Bertolino ML, Capani F, Genaro AM, Wald MRNiacin Modulates Pro-inflammatory Cytokine Secretion. A Potential Mechanism Involved in its Anti-atherosclerotic EffectOpen Cardiovasc Med J.(2013 Sep 20)
92.^Shashkin P1, Dragulev B, Ley KMacrophage differentiation to foam cellsCurr Pharm Des.(2005)
94.^Tontonoz P1, Nagy L, Alvarez JG, Thomazy VA, Evans RMPPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDLCell.(1998 Apr 17)
95.^Chinetti G1, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels BPPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathwayNat Med.(2001 Jan)
96.^Bortnick AE1, Rothblat GH, Stoudt G, Hoppe KL, Royer LJ, McNeish J, Francone OLThe correlation of ATP-binding cassette 1 mRNA levels with cholesterol efflux from various cell linesJ Biol Chem.(2000 Sep 15)
98.^Mantovani A1, Garlanda C, Locati MMacrophage diversity and polarization in atherosclerosis: a question of balanceArterioscler Thromb Vasc Biol.(2009 Oct)
99.^Martín-Fuentes P1, Civeira F, Recalde D, García-Otín AL, Jarauta E, Marzo I, Cenarro AIndividual variation of scavenger receptor expression in human macrophages with oxidized low-density lipoprotein is associated with a differential inflammatory responseJ Immunol.(2007 Sep 1)
100.^Bouhlel MA1, Derudas B, Rigamonti E, Dièvart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi GPPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory propertiesCell Metab.(2007 Aug)
101.^Lukasova M1, Malaval C, Gille A, Kero J, Offermanns SNicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cellsJ Clin Invest.(2011 Mar)
103.^Sibley CT1, Vavere AL, Gottlieb I, Cox C, Matheson M, Spooner A, Godoy G, Fernandes V, Wasserman BA, Bluemke DA, Lima JAMRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque studyHeart.(2013 Nov)
104.^Lee JM1, Robson MD, Yu LM, Shirodaria CC, Cunnington C, Kylintireas I, Digby JE, Bannister T, Handa A, Wiesmann F, Durrington PN, Channon KM, Neubauer S, Choudhury RPEffects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging studyJ Am Coll Cardiol.(2009 Nov 3)
105.^Kelly JJ1, Lawson JA, Campbell LV, Storlien LH, Jenkins AB, Whitworth JA, O'Sullivan AJEffects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjectsJ Hum Hypertens.(2000 Sep)
106.^Westphal S1, Borucki K, Taneva E, Makarova R, Luley CExtended-release niacin raises adiponectin and leptinAtherosclerosis.(2007 Aug)
107.^Warnholtz A1, Wild P, Ostad MA, Elsner V, Stieber F, Schinzel R, Walter U, Peetz D, Lackner K, Blankenberg S, Munzel TEffects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF studyAtherosclerosis.(2009 May)
108.^Nasser Figueiredo V1, Vendrame F2, Colontoni BA1, Quinaglia T1, Roberto Matos-Souza J3, Azevedo Moura F1, Coelho OR1, de Faria EC2, Sposito AC4Short-term effects of extended-release niacin with and without the addition of laropiprant on endothelial function in individuals with low HDL-C: a randomized, controlled crossover trialClin Ther.(2014 Jun 1)
109.^Stocker RAntioxidant activities of bile pigmentsAntioxid Redox Signal.(2004 Oct)
110.^Bregar U1, Jug B, Keber I, Cevc M, Sebestjen MExtended-release niacin/laropiprant improves endothelial function in patients after myocardial infarctionHeart Vessels.(2014 May)
111.^Chow DC1, Stein JH, Seto TB, Mitchell C, Sriratanaviriyakul N, Grandinetti A, Gerschenson M, Shiramizu B, Souza S, Shikuma CShort-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapyAIDS.(2010 Apr 24)
112.^Bays HE1, Rader DJDoes nicotinic acid (niacin) lower blood pressureInt J Clin Pract.(2009 Jan)
113.^Gadegbeku CA1, Dhandayuthapani A, Shrayyef MZ, Egan BMHemodynamic effects of nicotinic acid infusion in normotensive and hypertensive subjectsAm J Hypertens.(2003 Jan)
114.^Blankenhorn DH1, Selzer RH, Crawford DW, Barth JD, Liu CR, Liu CH, Mack WJ, Alaupovic PBeneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasoundCirculation.(1993 Jul)
115.^Brown BG1, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJSimvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary diseaseN Engl J Med.(2001 Nov 29)
117.^Whitney EJ1, Krasuski RA, Personius BE, Michalek JE, Maranian AM, Kolasa MW, Monick E, Brown BG, Gotto AM JrA randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical eventsAnn Intern Med.(2005 Jan 18)
119.^Maccubbin D1, Bays HE, Olsson AG, Elinoff V, Elis A, Mitchel Y, Sirah W, Betteridge A, Reyes R, Yu Q, Kuznetsova O, Sisk CM, Pasternak RC, Paolini JFLipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemiaInt J Clin Pract.(2008 Dec)
122.^Ganji SH1, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap MLNiacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cellsJ Lipid Res.(2004 Oct)
124.^Tunaru S1, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns SPUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effectNat Med.(2003 Mar)
125.^Eaton RP, Berman M, Steinberg DKinetic studies of plasma free fatty acid and triglyceride metabolism in manJ Clin Invest.(1969 Aug)
126.^Lauring B1, Taggart AK, Tata JR, Dunbar R, Caro L, Cheng K, Chin J, Colletti SL, Cote J, Khalilieh S, Liu J, Luo WL, Maclean AA, Peterson LB, Polis AB, Sirah W, Wu TJ, Liu X, Jin L, Wu K, Boatman PD, Semple G, Behan DP, Connolly DT, Lai E, Wagner JA, Wright SD, Cuffie C, Mitchel YB, Rader DJ, Paolini JF, Waters MG, Plump ANiacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppressionSci Transl Med.(2012 Aug 22)
127.^AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub WNiacin in patients with low HDL cholesterol levels receiving intensive statin therapyN Engl J Med.(2011 Dec 15)
128.^Wang W1, Basinger A, Neese RA, Christiansen M, Hellerstein MKEffects of nicotinic acid on fatty acid kinetics, fuel selection, and pathways of glucose production in womenAm J Physiol Endocrinol Metab.(2000 Jul)
129.^Nelson RH1, Vlazny D, Smailovic A, Miles JMIntravenous niacin acutely improves the efficiency of dietary fat storage in lean and obese humansDiabetes.(2012 Dec)
130.^Ahlström C1, Kroon T, Peletier LA, Gabrielsson JFeedback modeling of non-esterified fatty acids in obese Zucker rats after nicotinic acid infusionsJ Pharmacokinet Pharmacodyn.(2013 Dec)
131.^Ahlström C1, Peletier LA, Jansson-Löfmark R, Gabrielsson JFeedback modeling of non-esterified fatty acids in rats after nicotinic acid infusionsJ Pharmacokinet Pharmacodyn.(2011 Feb)
132.^Oh YT1, Oh KS, Choi YM, Jokiaho A, Donovan C, Choi S, Kang I, Youn JHContinuous 24-h nicotinic acid infusion in rats causes FFA rebound and insulin resistance by altering gene expression and basal lipolysis in adipose tissueAm J Physiol Endocrinol Metab.(2011 Jun)
133.^O'Kane MJ1, Trinick TR, Tynan MB, Trimble ER, Nicholls DPA comparison of acipimox and nicotinic acid in type 2b hyperlipidaemiaBr J Clin Pharmacol.(1992 Apr)
134.^Lai E1, Waters MG, Tata JR, Radziszewski W, Perevozskaya I, Zheng W, Wenning L, Connolly DT, Semple G, Johnson-Levonas AO, Wagner JA, Mitchel Y, Paolini JFEffects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humansJ Clin Lipidol.(2008 Oct)
135.^van der Hoorn JW1, de Haan W, Berbée JF, Havekes LM, Jukema JW, Rensen PC, Princen HMNiacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE-3Leiden.CETP miceArterioscler Thromb Vasc Biol.(2008 Nov)
136.^Hernandez M1, Wright SD, Cai TQCritical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in miceBiochem Biophys Res Commun.(2007 Apr 20)
137.^Barter PJ1, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall ARCholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosisArterioscler Thromb Vasc Biol.(2003 Feb 1)
138.^Barter PJ, Hopkins GJ, Calvert GDTransfers and exchanges of esterified cholesterol between plasma lipoproteinsBiochem J.(1982 Oct 15)
140.^Cinquin O1, Page KMGeneralized, switch-like competitive heterodimerization networksBull Math Biol.(2007 Feb)
141.^Lamon-Fava S1, Diffenderfer MR, Barrett PH, Buchsbaum A, Nyaku M, Horvath KV, Asztalos BF, Otokozawa S, Ai M, Matthan NR, Lichtenstein AH, Dolnikowski GG, Schaefer EJExtended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteinsArterioscler Thromb Vasc Biol.(2008 Sep)
143.^Blum CB, Levy RI, Eisenberg S, Hall M 3rd, Goebel RH, Berman MHigh density lipoprotein metabolism in manJ Clin Invest.(1977 Oct)
144.^Bays H1, Giezek H, McKenney JM, O'Neill EA, Tershakovec AMExtended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitusMetab Syndr Relat Disord.(2012 Aug)
145.^Duggal JK1, Singh M, Attri N, Singh PP, Ahmed N, Pahwa S, Molnar J, Singh S, Khosla S, Arora REffect of niacin therapy on cardiovascular outcomes in patients with coronary artery diseaseJ Cardiovasc Pharmacol Ther.(2010 Jun)
146.^Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill LBeneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass graftsJAMA.(1987 Jun 19)
147.^Brown G1, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HTRegression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein BN Engl J Med.(1990 Nov 8)
148.^Cashin-Hemphill L1, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DHBeneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-upJAMA.(1990 Dec 19)
149.^Brouwers MC, Stehouwer CDNiacin in cardiovascular patients receiving statinsN Engl J Med.(2012 Mar 29)
150.^Kahn SE1, Beard JC, Schwartz MW, Ward WK, Ding HL, Bergman RN, Taborsky GJ Jr, Porte D JrIncreased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistanceDiabetes.(1989 May)
152.^Chang AM1, Smith MJ, Galecki AT, Bloem CJ, Halter JBImpaired beta-cell function in human aging: response to nicotinic acid-induced insulin resistanceJ Clin Endocrinol Metab.(2006 Sep)
157.^Fraterrigo G1, Fabbrini E, Mittendorfer B, O'Rahilly S, Scherer PE, Patterson BW, Klein SRelationship between Changes in Plasma Adiponectin Concentration and Insulin Sensitivity after Niacin TherapyCardiorenal Med.(2012 Aug)
158.^Blond E1, Rieusset J2, Alligier M2, Lambert-Porcheron S1, Bendridi N2, Gabert L2, Chetiveaux M3, Debard C2, Chauvin MA2, Normand S1, Roth H4, de Gouville AC5, Krempf M3, Vidal H1, Goudable J1, Laville M1; “Niacin” Study GroupNicotinic acid effects on insulin sensitivity and hepatic lipid metabolism: an in vivo to in vitro studyHorm Metab Res.(2014 Jun)
159.^Plaisance EP1, Grandjean PW, Brunson BL, Judd RLIncreased total and high-molecular weight adiponectin after extended-release niacinMetabolism.(2008 Mar)
161.^Poynten AM1, Gan SK, Kriketos AD, O'Sullivan A, Kelly JJ, Ellis BA, Chisholm DJ, Campbell LVNicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid contentMetabolism.(2003 Jun)
163.^Dobbins RL1, Shearn SP, Byerly RL, Gao FF, Mahar KM, Napolitano A, Nachbaur GJ, Le Monnier de Gouville ACGSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitusDiabetes Obes Metab.(2013 Nov)
165.^Kokubun E1, Hirabara SM, Fiamoncini J, Curi R, Haebisch HChanges of glycogen content in liver, skeletal muscle, and heart from fasted ratsCell Biochem Funct.(2009 Oct)
166.^Beránek M1, Nováková D, Rozsíval P, Drsata J, Palicka VGlycation and advanced glycation end-products in laboratory experiments in vivo and in vitroActa Medica (Hradec Kralove).(2006)
167.^Tarwadi KV1, Agte VVEffect of micronutrients on methylglyoxal-mediated in vitro glycation of albuminBiol Trace Elem Res.(2011 Nov)
168.^Parker-Duffen JL1, Walsh K2Cardiometabolic effects of adiponectinBest Pract Res Clin Endocrinol Metab.(2014 Jan)
169.^Plaisance EP1, Lukasova M, Offermanns S, Zhang Y, Cao G, Judd RLNiacin stimulates adiponectin secretion through the GPR109A receptorAm J Physiol Endocrinol Metab.(2009 Mar)
170.^Wang-Fisher YL1, Han J, Guo WAcipimox stimulates leptin production from isolated rat adipocytesJ Endocrinol.(2002 Aug)
171.^Worm D1, Vinten J, Vaag A, Henriksen JE, Beck-Nielsen HThe nicotinic acid analogue acipimox increases plasma leptin and decreases free fatty acids in type 2 diabetic patientsEur J Endocrinol.(2000 Sep)
172.^Miles JM1, Park YS, Walewicz D, Russell-Lopez C, Windsor S, Isley WL, Coppack SW, Harris WSSystemic and forearm triglyceride metabolism: fate of lipoprotein lipase-generated glycerol and free fatty acidsDiabetes.(2004 Mar)
173.^[No authors listedBaron Theodore RoseLancet.(1978 Jun 24)
174.^Deivanayagam S1, Mohammed BS, Vitola BE, Naguib GH, Keshen TH, Kirk EP, Klein SNonalcoholic fatty liver disease is associated with hepatic and skeletal muscle insulin resistance in overweight adolescentsAm J Clin Nutr.(2008 Aug)
175.^Heemskerk MM1, van den Berg SA, Pronk AC, van Klinken JB, Boon MR, Havekes LM, Rensen PC, van Dijk KW, van Harmelen VLong-term niacin treatment induces insulin resistance and adrenergic responsiveness in adipocytes by adaptive downregulation of phosphodiesterase 3BAm J Physiol Endocrinol Metab.(2014 Apr 1)
177.^Lewis JE, Shimizu Y, Shimizu NNicotinamide inhibits adipocyte differentiation of 3T3-L1 cellsFEBS Lett.(1982 Sep 6)
178.^Purnell MR, Whish WJNovel inhibitors of poly(ADP-ribose) synthetaseBiochem J.(1980 Mar 1)
179.^Torres-Ramírez N1, Baiza-Gutman LA, García-Macedo R, Ortega-Camarillo C, Contreras-Ramos A, Medina-Navarro R, Cruz M, Ibáñez-Hernández MÁ, Díaz-Flores MNicotinamide, a glucose-6-phosphate dehydrogenase non-competitive mixed inhibitor, modifies redox balance and lipid accumulation in 3T3-L1 cellsLife Sci.(2013 Dec 18)
180.^Aktories K, Jakobs KH, Schultz GNicotinic acid inhibits adipocyte adenylate cyclase in a hormone--like mannerFEBS Lett.(1980 Jun 16)
181.^Aktories K, Jakobs KHIn vivo and in vitro desensitization of nicotinic acid-induced adipocyte adenylate cyclase inhibitionNaunyn Schmiedebergs Arch Pharmacol.(1982 Feb)
182.^Kraus D1, Yang Q1, Kong D2, Banks AS3, Zhang L2, Rodgers JT3, Pirinen E4, Pulinilkunnil TC5, Gong F5, Wang YC2, Cen Y6, Sauve AA6, Asara JM7, Peroni OD2, Monia BP8, Bhanot S8, Alhonen L4, Puigserver P3, Kahn BB2Nicotinamide N-methyltransferase knockdown protects against diet-induced obesityNature.(2014 Apr 10)
184.^Wang YX1, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR, Ham J, Kang H, Evans RMRegulation of muscle fiber type and running endurance by PPARdeltaPLoS Biol.(2004 Oct)
185.^Schuler M1, Ali F, Chambon C, Duteil D, Bornert JM, Tardivel A, Desvergne B, Wahli W, Chambon P, Metzger DPGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetesCell Metab.(2006 Nov)
186.^Ringseis R1, Rosenbaum S, Gessner DK, Herges L, Kubens JF, Mooren FC, Krüger K, Eder KSupplementing obese Zucker rats with niacin induces the transition of glycolytic to oxidative skeletal muscle fibersJ Nutr.(2013 Feb)
187.^Khan M1, Ringseis R, Mooren FC, Krüger K, Most E, Eder KNiacin supplementation increases the number of oxidative type I fibers in skeletal muscle of growing pigsBMC Vet Res.(2013 Sep 9)
188.^Khan M1, Couturier A, Kubens JF, Most E, Mooren FC, Krüger K, Ringseis R, Eder KNiacin supplementation induces type II to type I muscle fiber transition in skeletal muscle of sheepActa Vet Scand.(2013 Nov 22)
189.^Scholz K1, Kynast AM, Couturier A, Mooren FC, Krüger K, Most E, Eder K, Ringseis RSupplementing healthy rats with a high-niacin dose has no effect on muscle fiber distribution and muscle metabolic phenotypeEur J Nutr.(2014 Aug)
190.^Fukuwatari T1, Shibata K, Ishihara K, Fushiki T, Sugimoto EElevation of blood NAD level after moderate exercise in young women and miceJ Nutr Sci Vitaminol (Tokyo).(2001 Apr)
191.^Graham T, Sjøgaard G, Löllgen H, Saltin BNAD in muscle of man at rest and during exercisePflugers Arch.(1978 Aug 25)
193.^Sahlin K1, Katz A, Henriksson JRedox state and lactate accumulation in human skeletal muscle during dynamic exerciseBiochem J.(1987 Jul 15)
194.^Mach J1, Midgley AW, Dank S, Grant RS, Bentley DJThe effect of antioxidant supplementation on fatigue during exercise: potential role for NAD+(H)Nutrients.(2010 Mar)
195.^Zhang SJ1, Sandström ME, Lanner JT, Thorell A, Westerblad H, Katz AActivation of aconitase in mouse fast-twitch skeletal muscle during contraction-mediated oxidative stressAm J Physiol Cell Physiol.(2007 Sep)
196.^Cardoso SM1, Pereira C, Oliveira RMitochondrial function is differentially affected upon oxidative stressFree Radic Biol Med.(1999 Jan)
197.^Zandi-Nejad K1, Takakura A, Jurewicz M, Chandraker AK, Offermanns S, Mount D, Abdi RThe role of HCA2 (GPR109A) in regulating macrophage functionFASEB J.(2013 Nov)
199.^Cabrero A1, Laguna JC, Vázquez MPeroxisome proliferator-activated receptors and the control of inflammationCurr Drug Targets Inflamm Allergy.(2002 Sep)
200.^Moore KJ1, Rosen ED, Fitzgerald ML, Randow F, Andersson LP, Altshuler D, Milstone DS, Mortensen RM, Spiegelman BM, Freeman MWThe role of PPAR-gamma in macrophage differentiation and cholesterol uptakeNat Med.(2001 Jan)
201.^Ferreira RG1, Matsui TC, Gomides LF, Godin AM, Menezes GB, de Matos Coelho M, Klein ANiacin inhibits carrageenan-induced neutrophil migration in miceNaunyn Schmiedebergs Arch Pharmacol.(2013 Jun)
202.^Ferreira RG1, Matsui TC, Godin AM, Gomides LF, Pereira-Silva PE, Duarte ID, Menezes GB, Coelho MM, Klein ANeutrophil recruitment is inhibited by nicotinamide in experimental pleurisy in miceEur J Pharmacol.(2012 Jun 15)
203.^Kostylina G1, Simon D, Fey MF, Yousefi S, Simon HUNeutrophil apoptosis mediated by nicotinic acid receptors (GPR109A)Cell Death Differ.(2008 Jan)
204.^Hassa PO, Hottiger MOPARP-1 as Novel Coactivator of NF-κB in Inflammatory DisordersMolecular Biology Intelligence Unit.(2006)
205.^Szabó C1, Lim LH, Cuzzocrea S, Getting SJ, Zingarelli B, Flower RJ, Salzman AL, Perretti MInhibition of poly (ADP-ribose) synthetase attenuates neutrophil recruitment and exerts antiinflammatory effectsJ Exp Med.(1997 Oct 6)
207.^Whitacre CM1, Hashimoto H, Tsai ML, Chatterjee S, Berger SJ, Berger NAInvolvement of NAD-poly(ADP-ribose) metabolism in p53 regulation and its consequencesCancer Res.(1995 Sep 1)
209.^Jacobson EL1, Shieh WM, Huang ACMapping the role of NAD metabolism in prevention and treatment of carcinogenesisMol Cell Biochem.(1999 Mar)
212.^Thangaraju M1, Cresci GA, Liu K, Ananth S, Gnanaprakasam JP, Browning DD, Mellinger JD, Smith SB, Digby GJ, Lambert NA, Prasad PD, Ganapathy VGPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colonCancer Res.(2009 Apr 1)
214.^Hernandez C1, Molusky M, Li Y, Li S, Lin JDRegulation of hepatic ApoC3 expression by PGC-1β mediates hypolipidemic effect of nicotinic acidCell Metab.(2010 Oct 6)
215.^Lin J1, Yang R, Tarr PT, Wu PH, Handschin C, Li S, Yang W, Pei L, Uldry M, Tontonoz P, Newgard CB, Spiegelman BMHyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBPCell.(2005 Jan 28)
218.^McCulloch DK1, Kahn SE, Schwartz MW, Koerker DJ, Palmer JPEffect of nicotinic acid-induced insulin resistance on pancreatic B cell function in normal and streptozocin-treated baboonsJ Clin Invest.(1991 Apr)
220.^Chen D1, Steele AD, Lindquist S, Guarente LIncrease in activity during calorie restriction requires Sirt1Science.(2005 Dec 9)
222.^Landry J1, Slama JT, Sternglanz RRole of NAD(+) in the deacetylase activity of the SIR2-like proteinsBiochem Biophys Res Commun.(2000 Nov 30)
223.^Avalos JL1, Boeke JD, Wolberger CStructural basis for the mechanism and regulation of Sir2 enzymesMol Cell.(2004 Mar 12)
225.^Schmidt MT1, Smith BC, Jackson MD, Denu JMCoenzyme specificity of Sir2 protein deacetylases: implications for physiological regulationJ Biol Chem.(2004 Sep 17)
226.^Anderson RM1, Bitterman KJ, Wood JG, Medvedik O, Cohen H, Lin SS, Manchester JK, Gordon JI, Sinclair DAManipulation of a nuclear NAD+ salvage pathway delays aging without altering steady-state NAD+ levelsJ Biol Chem.(2002 May 24)
227.^Osborne R1, Carver RS, Mullins LA, Finlay DRPractical application of cellular bioenergetics to the care of aged skinBr J Dermatol.(2013 Jul)
228.^Kang S1, Duell EA, Fisher GJ, Datta SC, Wang ZQ, Reddy AP, Tavakkol A, Yi JY, Griffiths CE, Elder JT, et alApplication of retinol to human skin in vivo induces epidermal hyperplasia and cellular retinoid binding proteins characteristic of retinoic acid but without measurable retinoic acid levels or irritationJ Invest Dermatol.(1995 Oct)
229.^Bissett DL1, Oblong JE, Berge CANiacinamide: A B vitamin that improves aging facial skin appearanceDermatol Surg.(2005 Jul)
231.^Shalita AR, Smith JG, Parish LC, Sofman MS, Chalker DKTopical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgarisInt J Dermatol.(1995 Jun)
232.^Khodaeiani E, Fouladi RF, Amirnia M, Saeidi M, Karimi ERTopical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgarisInt J Dermatol.(2013 Aug)
233.^Hakozaki T1, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy REThe effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transferBr J Dermatol.(2002 Jul)
234.^Seiberg M1, Paine C, Sharlow E, Andrade-Gordon P, Costanzo M, Eisinger M, Shapiro SSInhibition of melanosome transfer results in skin lighteningJ Invest Dermatol.(2000 Aug)
235.^Nieves A1, Garza LADoes prostaglandin D2 hold the cure to male pattern baldnessExp Dermatol.(2014 Apr)
236.^Nelson AM1, Loy DE, Lawson JA, Katseff AS, Fitzgerald GA, Garza LAProstaglandin D2 inhibits wound-induced hair follicle neogenesis through the receptor, Gpr44J Invest Dermatol.(2013 Apr)
237.^Garza LA1, Liu Y, Yang Z, Alagesan B, Lawson JA, Norberg SM, Loy DE, Zhao T, Blatt HB, Stanton DC, Carrasco L, Ahluwalia G, Fischer SM, FitzGerald GA, Cotsarelis GProstaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopeciaSci Transl Med.(2012 Mar 21)
238.^Davis MG1, Thomas JH, van de Velde S, Boissy Y, Dawson TL Jr, Iveson R, Sutton KA novel cosmetic approach to treat thinning hairBr J Dermatol.(2011 Dec)
239.^Qiang JK1, Wong YC, Siderowf A, Hurtig HI, Xie SX, Lee VM, Trojanowski JQ, Yearout D, B Leverenz J, Montine TJ, Stern M, Mendick S, Jennings D, Zabetian C, Marek K, Chen-Plotkin ASPlasma apolipoprotein A1 as a biomarker for Parkinson diseaseAnn Neurol.(2013 Jul)
240.^Swanson CR1, Li K, Unger TL, Gallagher MD, Van Deerlin VM, Agarwal P, Leverenz J, Roberts J, Samii A, Gross RG, Hurtig H, Rick J, Weintraub D, Trojanowski JQ, Zabetian C, Chen-Plotkin ASLower plasma Apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotypeMov Disord.(2014 Sep 16)
241.^Maarouf CL1, Beach TG, Adler CH, Shill HA, Sabbagh MN, Wu T, Walker DG, Kokjohn TA, Roher AE; Arizona PD ConsortiumCerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjectsNeurol Res.(2012 Sep)
242.^Chahine LM1, Stern MB, Chen-Plotkin ABlood-based biomarkers for Parkinson's diseaseParkinsonism Relat Disord.(2014 Jan)
245.^Hellenbrand W1, Boeing H, Robra BP, Seidler A, Vieregge P, Nischan P, Joerg J, Oertel WH, Schneider E, Ulm GDiet and Parkinson's disease. II: A possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control studyNeurology.(1996 Sep)
246.^Ross GW1, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki KH, Blanchette PL, Curb JD, Popper JS, White LRAssociation of coffee and caffeine intake with the risk of Parkinson diseaseJAMA.(2000 May 24-31)
247.^Abbott RD1, Ross GW, White LR, Sanderson WT, Burchfiel CM, Kashon M, Sharp DS, Masaki KH, Curb JD, Petrovitch HEnvironmental, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia Aging StudyJ Neurol.(2003 Oct)
249.^Whelan AM1, Price SO, Fowler SF, Hainer BLThe effect of aspirin on niacin-induced cutaneous reactionsJ Fam Pract.(1992 Feb)
250.^Thakkar RB1, Kashyap ML, Lewin AJ, Krause SL, Jiang P, Padley RJAcetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemiaAm J Cardiovasc Drugs.(2009)
251.^Cefali EA1, Simmons PD, Stanek EJ, McGovern ME, Kissling CJAspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulationInt J Clin Pharmacol Ther.(2007 Feb)
253.^Dishy V1, Liu F, Ebel DL, Atiee GJ, Royalty J, Reilley S, Paolini JF, Wagner JA, Lai EEffects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptomsJ Clin Pharmacol.(2009 Apr)
254.^Dunn RT1, Ford MA, Rindone JP, Kwiecinski FALow-Dose Aspirin and Ibuprofen Reduce the Cutaneous Reactions Following Niacin AdministrationAm J Ther.(1995 Jul)
255.^Moriarty PM1, Backes J, Dutton JA, He J, Ruisinger JF, Schmelzle KApple pectin for the reduction of niacin-induced flushingJ Clin Lipidol.(2013 Mar-Apr)
257.^Schwartz SE1, Levine RA, Weinstock RS, Petokas S, Mills CA, Thomas FDSustained pectin ingestion: effect on gastric emptying and glucose tolerance in non-insulin-dependent diabetic patientsAm J Clin Nutr.(1988 Dec)
258.^de Murcia G1, Schreiber V, Molinete M, Saulier B, Poch O, Masson M, Niedergang C, Ménissier de Murcia JStructure and function of poly(ADP-ribose) polymeraseMol Cell Biochem.(1994 Sep)
259.^Virág L1, Szabó CThe therapeutic potential of poly(ADP-ribose) polymerase inhibitorsPharmacol Rev.(2002 Sep)
260.^Hageman GJ1, Stierum RHNiacin, poly(ADP-ribose) polymerase-1 and genomic stabilityMutat Res.(2001 Apr 18)
263.^Trucco C1, Oliver FJ, de Murcia G, Ménissier-de Murcia JDNA repair defect in poly(ADP-ribose) polymerase-deficient cell linesNucleic Acids Res.(1998 Jun 1)
264.^Wang ZQ1, Stingl L, Morrison C, Jantsch M, Los M, Schulze-Osthoff K, Wagner EFPARP is important for genomic stability but dispensable in apoptosisGenes Dev.(1997 Sep 15)
265.^Trucco C1, Rolli V, Oliver FJ, Flatter E, Masson M, Dantzer F, Niedergang C, Dutrillaux B, Ménissier-de Murcia J, de Murcia GA dual approach in the study of poly (ADP-ribose) polymerase: in vitro random mutagenesis and generation of deficient miceMol Cell Biochem.(1999 Mar)
266.^García-Parra J1, Dalmases A1, Morancho B2, Arpí O1, Menendez S1, Sabbaghi M1, Zazo S3, Chamizo C3, Madoz J3, Eroles P4, Servitja S1, Tusquets I5, Yelamos J6, Lluch A7, Arribas J8, Rojo F9, Rovira A1, Albanell J10Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancerEur J Cancer.(2014 Aug 12)
267.^Lee HJ1, Yoon C, Schmidt B, Park do J, Zhang AY, Erkizan HV, Toretsky JA, Kirsch DG, Yoon SSCombining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damageMol Cancer Ther.(2013 Nov)
268.^Fong PC1, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JSInhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriersN Engl J Med.(2009 Jul 9)
270.^Masiello P1, Broca C, Gross R, Roye M, Manteghetti M, Hillaire-Buys D, Novelli M, Ribes GExperimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamideDiabetes.(1998 Feb)
272.^Ellsworth MA1, Anderson KR2, Hall DJ2, Freese DK3, Lloyd RM4Acute liver failure secondary to niacin toxicityCase Rep Pediatr.(2014)
273.^Daul AM1, Beuhler MCNiacin toxicity resulting from urine drug test evasionJ Emerg Med.(2011 Sep)
274.^Mittal MK1, Florin T, Perrone J, Delgado JH, Osterhoudt KCToxicity from the use of niacin to beat urine drug screeningAnn Emerg Med.(2007 Nov)
276.^Mullin GE1, Greenson JK, Mitchell MCFulminant hepatic failure after ingestion of sustained-release nicotinic acidAnn Intern Med.(1989 Aug 1)